GSK Pharma Share Price Target 2024 To 2030 –Â GSK Pharmaceuticals is a multinational healthcare company that deals with the provision of outstanding pharmaceutical products and services by coming up with appropriate medicines, vaccines, and healthcare products. To date, acting r & d, GSK focuses on essential health problems, including respiratory illnesses, HIV/AIDS, cancer, and autoimmune diseases. The company specializes in vaccines; it develops solutions for ailments such as influenza, hepatitis, and HPV, among others.
With a presence in over 100 countries, GSK anticipates a role in enhancing the quality of life of patients across the globe and securing availability of preventive healthcare commodities, and environmental balance.Â
GSK Pharma Share Price Current Market Overview
- Today’s Open: 2815.00
- Today’s High: 2850.10
- Today’s Low: 2772.00
- Current Share Price: 2825.00
- Market Capital: 47.99K Cr
- P/E: 74.79
- Dividend Yield: 1.13%
- 52 Week High: 3088.00
- 52 Week Low: 1385.05
GSK Pharma Share Price Current Graph
Share Price Target Tomorrow From 2024 To 2030
The given share target prices are for upcoming years, which are based on market analysis, industrial trends, and professional expectations.
| S.NO. | Share Price Target Years | Share Target Value |
|
|
2024 | 3320 |
|
|
2025 | 4752 |
|
|
2026 | 5112 |
|
|
2027 | 6524 |
|
|
2028 | 7948 |
|
|
2029 | 8306 |
|
|
2030 | 9560 |
Shareholding Pattern For GSK PharmaÂ
- Promoters: 75.00%
- Retail And Others: 13.48%
- Mutual Funds: 4.71%
- Foreign Institutions: 4.02%
- Other Domestic Institutions: 2.80%
GSK Pharma Annual Income Statement
Here is the comparison between revenue and net income.
The following data shows the annual income statement of GSK Pharmaceuticals.
| Particulars | Info 2024 | Y/Y Change |
| Revenue | 34.54B | 6.21% (+) |
| Operating Expenses | 12.59B | 5.03% (+) |
| Net Income | 5.90B | 3.39% (-) |
| Net Profit Margin | 17.08 | 9.05% (-) |
| Earning Per Share | 41.14 | 14.60% (+) |
| EBITDA | 8.81B | 11.69% (+) |
| Effective Tax Rate | 27.72% | N/A |
Challenges For GSK Pharma Share Price.
R&D Risks
High costs and risks involved in the manufacturing of new drugs could affect the revenue of the company.
Regulatory Hurdles
Government control measures and regulatory changes that may lead to the postponement of new drugs in the market will impair market confidence.
Competition
Greater competition from other generic drug producers and other pharmaceutical companies.
Currency Fluctuations
This poses a major threat to GSK since it has operations in the international market, therefore it is sensitive to fluctuations in the foreign exchange rates.
